
<td align="center" class="tbcolor10" colspan="2" valign="top">
<table border="0" cellpadding="0" height="100%" width="100%">
<tbody><tr><td align="right" height="35px" style="font-size:9pt">
<a href="javascript:window.close()" title="关闭本窗口">关闭窗口</a>｜<a href="print.asp?id=477722" target="_blank" title="打印本页内容">打印张贴版</a>    

</td></tr>
<tr>
<td align="center" height="500" valign="top">
<table border="0" cellpadding="4" cellspacing="0" height="100%" style="border-collapse: collapse;word-break:break-all;" width="86%">
<tbody><tr>
<td align="center" height="80px"><span style="font-family:方正小标宋简体;font-size: 25px;color: #C70E5C">【学术讲座】铂类抗肿瘤药物的可控激活与递送</span></td>
</tr>
<tr>
<td align="center" height="50px" style="font-size: 9pt"><font color="#808080">医学部　2022/8/4 16:45:00</font><br/> 
<font color="#F8F8F8" style="font-size:9pt">（钟沛基 2022280095）</font></td>
</tr>
<tr>
<td height="300" valign="top">
<p class="MsoNormal" style="text-align: center;"><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">报告题目：</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">Controllable
activation and delivery of platinum anticancer prodrugs</span></p><p class="MsoNormal"><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">报告人：朱光宇教授</span><span style="font-size: 12pt; font-family: Calibri, sans-serif;"> <span lang="EN-US"><o:p></o:p></span></span></p><p class="MsoNormal"><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">主持人：王志刚</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;"><o:p></o:p></span></p><p class="MsoNormal"><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">时间：</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">2022</span><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">年</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">8</span><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">月</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">9</span><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">号</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;"> 16:30-17</span><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">：</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">30<o:p></o:p></span></p><p class="MsoNormal"><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">地点：腾讯会议（</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">ID</span><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">号：</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;">647-882-497</span><span style="font-size: 12pt; font-family: 微软雅黑, sans-serif;">）</span><span lang="EN-US" style="font-size: 12pt; font-family: Calibri, sans-serif;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style='font-family:"Calibri",sans-serif;
mso-fareast-font-family:微软雅黑;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:
minor-bidi'> 报</span><span style="font-family: 微软雅黑, sans-serif;">告人简介：</span><span style="font-family: Calibri, sans-serif;"> <span lang="EN-US">       </span></span></p><p class="MsoNormal" style="text-indent:10.5pt;mso-char-indent-count:1.0;
layout-grid-mode:char;mso-layout-grid-align:none"><span lang="EN-US" style='font-family:"Calibri",sans-serif;mso-fareast-font-family:微软雅黑;
mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi'> Dr. Guangyu Zhu is an Associate Professor at
the Department of Chemistry, City University of Hong Kong. Dr. Zhu’s research
interest lies at the interface of chemistry and biology, focusing on anticancer
drug development and mechanism. His current research projects include
development of photoactivatable anticancer prodrugs, synthesis and biological
evaluation of novel metal-based anticancer agents, and development of
cancer-specific nanomedicine to conquer cisplatin resistance. His research work
has been published in Nature series, Chem, JACS, Angew, PNAS, etc. Currently he
is the Editorial Advisory Board member of the Journal of Biological Inorganic
Chemistry and member of Asian Biological Inorganic Chemistry (AsBIC) Steering
Committee.</span></p><p class="MsoNormal" style="text-indent:10.5pt;mso-char-indent-count:1.0;
layout-grid-mode:char;mso-layout-grid-align:none"><span style="text-indent: 10.5pt; font-family: 微软雅黑, sans-serif;">报告内容：</span><span lang="EN-US" style="text-indent: 10.5pt; font-family: Calibri, sans-serif;">Despite the broad clinical applications of platinum-based
anticancer drugs including cisplatin, their side effects and resistance issues
have encouraged researchers to look for novel metal-based anticancer complexes.
Non-traditional platinum compounds, especially Pt(IV) complexes, have been
extensively studied, and they hold great promise to be further developed as the
next-generation platinum drugs. Controllable activation of prodrugs within a
tumor is particularly attractive because of their low damage to normal tissue.
In this presentation, I will introduce the design, photoactivation mechanism,
and antitumor activity of visible light-activatable Pt(IV) prodrugs. These
small-molecule prodrugs have controllable activation properties and display
superior antitumor activity both in vitro and in vivo. In addition, our recent
progress in erythrocyte-delivered Pt(IV) prodrug and nanoprodrug for enhanced
circulation will also be introduced. The controllable activation property and
superior antitumor activity of these prodrugs may suggest a practical way to
reduce the adverse effects and conquer drug resistance of traditional platinum
chemotherapy.</span></p><link href="/szu.css" rel="stylesheet" type="text/css"/><link href="/szu.css" rel="stylesheet" type="text/css"/><link href="/szu.css" rel="stylesheet" type="text/css"/><link href="/szu.css" rel="stylesheet" type="text/css"/><link href="/szu.css" rel="stylesheet" type="text/css"/></td>
</tr>
<tr><td height="0" style="font-size: 9pt"></td></tr>
<tr><td align="right" style="font-size: 9pt">（更新于2022/8/6 16:57:00）<br/> </td></tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
